Fig. 3
From: Increased sialylation of site specific O-glycoforms of hemopexin in liver disease
Direct quantification of S-HPX at progressing stages of liver disease. Direct quantification of S-HPX in samples of the following groups of controls and HALT-C participants in the discovery sample set: a disease-free controls (n = 23), liver fibrosis (n = 22), and cirrhosis (n = 24) patients; b 23 healthy volunteers at four different blood draw times. The box and whisker plots represents median, 25th–75th percentile, range of values, and outliers; *significantly different at p < 0.01 from control and **from the fibrosis group